The effect of Melatonin on stress induced hyperglycemia

Evaluating the effect of Melatonin on stress induced hyperglycemia and insulin resistance in critically ill patients: a randomized double-blind clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100107003014N23

Enrollment

104

Registered

2020-04-04

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress induced hyperglycemia. Hyperglycemia, unspecified

Interventions

Intervention 1: Intervention group: Melatonin tablet ( made by Razak company) is prescribed twice daily , each time 2 tablets for 3 days for patients. Intervention 2: Control group: would receive plac

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age above 18 years old Stress induced hyperglycemia (Blood sugar above 140) in the first 24 hours of admission in intensive care unit

Exclusion criteria

Exclusion criteria: Diabetes HbA1C>7.5 Receiving glucocorticoids Pregnant women Allergy to Melatonin or its analogs

Design outcomes

Primary

Measure	Time frame
Blood sugar. Timepoint: Before intervention and the 4th day of intervention. Method of measurement: Blood test.;Homeostasis model assessment of insulin resistance. Timepoint: Before intervention and the 4th day of intervention. Method of measurement: Blood autoanalyser device? enzyme immunoassay and formula.;Homeostasis model assessment of adiponectin. Timepoint: Before intervention and the 4th day of intervention. Method of measurement: Blood autoanalyser device? enzyme immunoassay and formula.	—

Measure

Time frame

Blood sugar. Timepoint: Before intervention and the 4th day of intervention. Method of measurement: Blood test.;Homeostasis model assessment of insulin resistance. Timepoint: Before intervention and the 4th day of intervention. Method of measurement: Blood autoanalyser device? enzyme immunoassay and formula.;Homeostasis model assessment of adiponectin. Timepoint: Before intervention and the 4th day of intervention. Method of measurement: Blood autoanalyser device? enzyme immunoassay and formula.

—

Secondary

Measure	Time frame
Delirium. Timepoint: Before intervention and 7th day of intervention. Method of measurement: Form (Reliability and Validity of the Richmond Agitation-Sedation Scale )(RASS).;Ventilator dependency. Timepoint: Before intervention and 7th day of intervention. Method of measurement: Form (have or do not have).;Quick sofa criteria. Timepoint: Before intervention and 7th day of intervention. Method of measurement: Form ( based on respiratory rate? blood pressure, change in mental status).;Admission days in intensive care unit. Timepoint: Up to last day of intensive care unit admission. Method of measurement: Data collecting form.	—

Measure

Time frame

Delirium. Timepoint: Before intervention and 7th day of intervention. Method of measurement: Form (Reliability and Validity of the Richmond Agitation-Sedation Scale )(RASS).;Ventilator dependency. Timepoint: Before intervention and 7th day of intervention. Method of measurement: Form (have or do not have).;Quick sofa criteria. Timepoint: Before intervention and 7th day of intervention. Method of measurement: Form ( based on respiratory rate? blood pressure, change in mental status).;Admission days in intensive care unit. Timepoint: Up to last day of intensive care unit admission. Method of measurement: Data collecting form.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Ala

Mazandaran University of Medical Sciences

sala@mazums.ac.ir+98 11 3354 3083

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026